Anti-MPL neutralizing antibody

Current understanding

To be populated as evidence accumulates.

2026-09-24 — Selective dependency of CALR-mutant myeloproliferative neoplasms on TYK2 signaling.: cross-connection with deucravacitinib-tyk2-mpn: TYK2 dependency in MPL-mutant MPN converges with anti-MPL approaches on the same signaling axis driving CALR/MPL-driven disease. (novelty: 5)
2026-09-03 — Targeting Thrombopoietin/MPL Signaling to Mitigate JAK2V617F-Driven Cardiac Microvascular Disease.: Preclinical (JAK2V617F chimeric mouse model): anti-MPL neutralizing antibody reversed cardiac microvascular disease under cardiometabolic stress by blocking upregulated endocardial thrombopoietin/MPL signaling, restoring endocardial integrity and coronary microvascular density. (novelty: 4)